CHU Strasbourg Hpital Hautepierre

Strasbourg, Bas Rhin 67098

1 studies enrolling now · 10 studies all time

What they study most

Alzheimer's Disease, Alzheimer's Disease Dementia, Hepatitis Delta Virus, Invasive Fungal Infections, Mild Cognitive Impairment Due to Alzheimer's Disease, Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis, Rheumatoid Arthritis

Studies at this site

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — Recruiting now
• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age — Running, not enrolling
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — Running, not enrolling
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options — Completed
• Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a — Completed
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease — Stopped early
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early